Dactinomycin

CHEMBL1554 Phase 4 Disetujui Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1255.4 g/mol

LogP

3.8

Phase

4

An antibiotic-derived antineoplastic agent that intercalates into DNA and blocks RNA polymerase, preventing protein synthesis in cancer cells; used for Wilms' tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia. It is one of the oldest chemotherapy agents still in clinical use.

Berat Molekul

1255,4000 g/mol

LogP

3,80

TPSA

356,00 Å²

Lipinski RO5

Gagal

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O

InChI

InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

Molecular Formula

C62H86N12O16

HBD / HBA

5 / 18

Ikatan yang Dapat Dirotasi

8

Atom Berat

90

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

An antibiotic-derived antineoplastic agent that intercalates into DNA and blocks RNA polymerase, preventing protein synthesis in cancer cells; used for Wilms' tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia. It is one of the oldest chemotherapy agents still in clinical use.

Yes, Dactinomycin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1554. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 457193. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Dactinomycin di PillFYI

Struktur

Data Cepat

Rumus: C62H86N12O16
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.